The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
995
February 28, 1997
View Complete Issue         Table of Contents 2019 
Reteplase (Retavase)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Reteplase (Retavase)
February 28, 1997 (Issue: 995)
Reteplase (Retavase - Boehringer Mannheim), a recombinant protein derivative of human tissue plasminogen activator (t-PA), has been marketed in the USA for thrombolysis in patients with acute myocardial infarction.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Reteplase (Retavase)
Article code: 995a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.